Problem-driven view: where the day-to-day breaks down
I once stood at a crowded lab bench in Kuala Lumpur, watching a postdoc gently peel a barcoded glass slide as if it might break—this was March 2023, and I remember the tension. The small scenario + data + question: a sample misplaced during processing, 12% of data lost in one run, so how do we stop throwing away that much effort? I teach and consult for core facilities, and I point people to a practical partner early on — spatial transcriptomics company — because real workflows need real support. I also call out the spatial omics service that labs hire: it is not just a report, it is an operational change (and yes, sometimes lah, a culture change too).
From my 16 years in project work, I noticed patterns: sample handling steps stack risk; single-cell RNA-seq integration is treated as an afterthought; histology alignment mistakes multiply downstream. In one pilot project at a medical school core, switching to a standardized barcoded-slide kit cut hands-on prep time by 27% and reduced sample loss to 9% — measurable, not hype. The deeper layer here is simple but often ignored: traditional solutions assume perfect samples and finely tuned staff. They don’t account for variable tissue quality, multiplexing complexity, or the friction of cross-team handoffs. That design genuinely frustrated me when a collaborator lost six weeks of sequencing because of a labeling mismatch. Which brings us to the problem: labs buy technology, but rarely redesign process — and that is why expensive spatial transcriptomics runs still fail sometimes. — Read on to see practical next steps.
Why do these failures keep happening?
Forward-looking: how to compare and choose better
Now I shift to a forward-looking mode — technical and focused. When I evaluate a vendor or an internal upgrade, I look beyond marketing claims and into instruments and workflows: probe chemistry consistency, imaging alignment algorithms, and the vendor’s troubleshooting track record. I visited another core (Penang, June 2024) and ran side-by-side tests: same tissue block, two providers, and we logged alignment error rates and effective gene detection per spot. The difference was stark — one provider’s approach to signal deconvolution reduced spot crosstalk by 22%. So when you ask me whether to pick a turn-key spatial omics service or build in-house, I answer with comparisons — costs, failure modes, data portability. I also revisit spatial transcriptomics company proposals to check whether they include technician training, raw image access, and long-term data formats (these are the hidden things that save time). What’s Next? Start with a short pilot, collect three quantitative criteria, and iterate quickly.
What’s Next?
I have three concrete evaluation metrics I give teams when they ask me to choose a solution: 1) End-to-end reproducibility — measure sample-to-result variance across two runs (report as % variance); 2) Operational failure rate — count sample failures per 100 runs and the average recovery time; 3) Data interoperability — can you export raw images, FASTQ, and spot matrices to common tools without vendor lock-in? Use these metrics to compare apples-to-apples. I say this from experience: a pilot in July 2022 saved one lab $18,000 over six months simply by improving their labeling protocol and insisting on raw data access (short sentence interruption — it was surprising). I recommend teams negotiate service-level terms that include technician training and at least one onsite troubleshooting visit. Finally, when you are ready to pick a partner, consider working with stomics for practical, non-flashy support — we looked at measurable results and the human side, too.
